Chongqing Zhifei Biological Products (300122.SZ) announced that its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. (...)
According to the Zhihu Finance APP, Chongqing Zhifei Biological Products (300122.SZ) announced that its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. ("Zhifei Longkema") has received the acceptance notice for the clinical trial application of the trivalent influenza virus split vaccine (ZFA02 adjuvant) ("adjuvant trivalent influenza vaccine") from the National Medical Products Administration. The clinical trial application accepted for the adjuvant trivalent influenza vaccine includes the company's independently developed ZFA02 adjuvant, which after vaccination can stimulate the body to produce a humoral immune response and cellular immune response against the influenza virus antigen hemagglutinin (HA), used for the prevention of influenza caused by vaccine-related strains of the influenza virus.
